Sugi Predict

Sugi Predict / Compounds / SCHEMBL4151624

SCHEMBL4151624

SCHEMBL4151624

Fc1ccc(C=Cc2nn(C(c3ccccc3)(c3ccccc3)c3ccccc3)c3cnc(Cl)nc23)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 2/20 0.37
▸ MAPT P10636 6/20 0.37
▸ KDM4E B2RXH2 4/20 0.37
▸ ALDH1A1 P00352 4/20 0.37
▸ L3MBTL1 Q9Y468 4/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ GRM4 Q14833 1/20 0.34
▸ HTR2A P28223 2/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ ENPP2 Q13822 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ CASP3 P42574 1/20 0.32
▸ SENP8 Q96LD8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4151621 1.00 NFE2L2 (0.37) NFE2L2MAPTKDM4EALDH1A1L3MBTL1
SCHEMBL4136220 0.74 EGFR (0.33) MAPT
SCHEMBL6226378 0.73 NFE2L2 (0.37) NFE2L2MAPTKDM4EALDH1A1L3MBTL1
SCHEMBL6226375 0.73 NFE2L2 (0.37) NFE2L2MAPTKDM4EALDH1A1L3MBTL1
SCHEMBL4152131 0.72 NFE2L2 (0.43) NFE2L2MAPTKDM4EALDH1A1MEN1
SCHEMBL4152134 0.72 NFE2L2 (0.43) NFE2L2MAPTKDM4EALDH1A1MEN1
SCHEMBL4149708 0.71 NFE2L2 (0.37) NFE2L2MAPTKDM4EALDH1A1L3MBTL1
SCHEMBL4144054 0.71 NFE2L2 (0.37) NFE2L2MAPTKDM4EALDH1A1L3MBTL1
SCHEMBL4144061 0.71 NFE2L2 (0.37) NFE2L2MAPTKDM4EALDH1A1L3MBTL1
SCHEMBL4149703 0.71 NFE2L2 (0.37) NFE2L2MAPTKDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND OHI NORIHITO 2009-02-26 — — US disclosed
US-7429609-B2 Pyrazole compound and medicinal composition containing the same EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-09-30 — — US disclosed
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-24 — — US disclosed
US-20050208582-A1 Pyrazole compounds and pharmaceutical compositions comprising the compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-09-22 — — US disclosed
EP-1510516-A1 PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME Eisai Co., Ltd. (JP) 2005-03-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND CNKSR1, NR3C2, CSNK2B NFE2L2 434/4885MAPT 2811/4885KDM4E 2622/4885
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same CNKSR1, NR3C2, CSNK2B NFE2L2 413/4885MAPT 3014/4885KDM4E 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.